North Carolina is currently home to 2670 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Durham, Charlotte, Winston-Salem and Chapel Hill. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Navigation Study: Durham
Recruiting
The purpose of the proposed study is to evaluate the implementation and impact of a new, community-wide prevention program, "Navigation", on maternal and infant health and well-being. This program recruits mothers at the OB/GYN or pediatrician's office and provides up to several visits (prenatally, 12 months, 24 months, and 36 months) to assess family needs, establishes connections between the family and primary health care or other community providers, and then follows up one month later to con... Read More
Gender:
All
Ages:
0 years and above
Trial Updated:
03/15/2024
Locations: Duke University, Durham, North Carolina
Conditions: Prenatal; Postnatal
Use of an Integrated Orthotic and Rehabilitation Initiative for Treatment of Lower Extremity Musculoskeletal Disorders
Recruiting
The Intrepid Dynamic Exoskeletal Orthosis (IDEO) is a custom, energy storage and return ankle orthosis proven to improve functional ability when coupled with a customized high-intensity rehabilitation program. The Return to Performance (RTP) clinical pathway is the civilian version of the evidence-based Return To Run (RTR) clinical pathway. Together, the CUSTOMIZED EXOSKELETAL ORTHOSIS and RTP form a novel orthotic and rehabilitation initiative. A diverse group of patients has utilized the pathw... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
03/14/2024
Locations: Carolinas Medical Center, Charlotte, North Carolina
Conditions: Musculoskeletal Injury
Collaborative Care in Posttraumatic Epilepsy
Recruiting
The purpose of this research is to evaluate a 6 month change in quality of life in subjects who receive collaborative care calls compared to those subjects who receive usual neurology care. This is a 2-site trial comparing a 24 week neurology-based collaborative care program to usual neurology care among a total of 60 adults with post-traumatic epilepsy.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/14/2024
Locations: Atrium Health Wake Forest Baptist, Winston-Salem, North Carolina
Conditions: Epilepsy, Post-Traumatic
Percutaneous or Surgical Repair In Mitral Prolapse And Regurgitation for ≥60 Year-olds (PRIMARY)
Recruiting
This is a prospective, multicenter, open-label, randomized trial comparing mitral valve (MV) transcatheter edge-to-edge repair (TEER) to surgical repair (1:1 ratio) in patients with primary, degenerative mitral regurgitation (MR). The trial will be conducted in the U.S., Canada, Germany and the United Kingdom, and is designed as a strategy trial. Thus, all devices legally marketed for TEER of primary degenerative MR in a particular country are eligible to be used in this trial.
Gender:
All
Ages:
65 years and above
Trial Updated:
03/14/2024
Locations: Duke University Hospital, Durham, North Carolina
Conditions: Mitral Valve Regurgitation
Congenital Athymia Patient Registry
Recruiting
This Congenital Athymia Patient Registry is an observational exposure-based registry study. It uses a prospective cohort design to follow patients who have been treated with RETHYMIC. Clinical studies conducted with investigational RETHYMIC showed that treatment can result in immune reconstitution and prolong life. This treatment-based registry is being conducted to learn more about the reconstitution process following treatment and the impact of treatment on longer-term survival and the occurr... Read More
Gender:
All
Ages:
Between 0 years and 21 years
Trial Updated:
03/13/2024
Locations: Duke University School of Medicine, Durham, North Carolina
Conditions: Complete DiGeorge Anomaly, Complete DiGeorge Syndrome, Congenital Athymia
Role of Ablative Radiotherapy in the Management of Metastatic Disease: A Patient Data Registry
Recruiting
The purpose of this study is to provide a registry of participants in order to assess the acute adverse event rates following ablative radiotherapy for metastatic disease.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/13/2024
Locations: Duke Cancer Institute Cary, Cary, North Carolina
Conditions: Oligometastasis, Metastatic Cancer
First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia
Recruiting
This first-in-human (FIH) dose-escalation and dose-validation/expansion study will assess ziftomenib, a menin-MLL(KMT2A) inhibitor, in patients with relapsed or refractory acute myeloid leukemia (AML) as part of Phase 1. In Phase 2, assessment of ziftomenib will continue in patients with NPM1-m AML.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/13/2024
Locations: Duke Cancer Institute, Durham, North Carolina
Conditions: Advanced Malignant Neoplasm, Acute Myeloid Leukemia, Mixed Lineage Leukemia, Mixed Lineage Acute Leukemia, Acute Leukemia of Ambiguous Lineage, Mixed Phenotype Acute Leukemia
Novel 3D Hematological Malignancy Organoid to Study Disease Biology and Chemosensitivity
Recruiting
The objective of this project is to compare chemosensitivity between chemotherapy combinations in bone marrow aspirates using 3D organoid models. The investigators overarching hypothesis is that 3D organoids are ideal to test chemosensitivity in real time, to provide personalized medicine and guidance in the setting of relapsed hematologic malignancy and potentially other cancers.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/13/2024
Locations: Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, North Carolina
Conditions: Hematologic Malignancy
ALTERRA Post-Approval Study
Recruiting
This study will monitor device performance and outcomes in subjects undergoing implantation of the Edwards SAPIEN 3 Transcatheter Pulmonary Valve System with Alterra Adaptive Prestent in the post-approval setting
Gender:
All
Ages:
All
Trial Updated:
03/12/2024
Locations: Duke University, Durham, North Carolina
Conditions: Pulmonary Valve Insufficiency, Complex Congenital Heart Defect, Tetralogy of Fallot, Pulmonary Regurgitation, RVOT Anomaly
Specialty Compared to Oncology Delivered Palliative Care for Patients With Acute Myeloid Leukemia
Recruiting
This research study is evaluating whether primary palliative care is an alternative strategy to specialty palliative care for improving quality of life, symptoms, mood, coping, and end of life outcomes in patients with acute myeloid leukemia (AML).
Gender:
All
Ages:
Between 18 years and 120 years
Trial Updated:
03/12/2024
Locations: University of North Carolina at Chapel Hill, Chapel Hill, North Carolina
Conditions: Relapsed Adult AML, Primary Refractory Acute Myeloid Leukemia, High Risk Acute Myeloid Leukemia
A Prospective Registry of Pediatric Cellular Therapy Patients at Risk for Endothelial Dysfunction, Sinusoidal Obstruction Syndrome and/or Multi-Organ Dysfunction Syndrome (MODS).
Recruiting
This is a prospective international multi-center registry and biorepository trial of children and adolescents/young adults (AYA) undergoing hematopoietic cell transplantation (HCT) to assess the impact of endotheliopathies in the HCT setting as a contributor of significant morbidity and mortality.
Gender:
All
Ages:
Between 0 years and 26 years
Trial Updated:
03/12/2024
Locations: Duke University, Durham, North Carolina
Conditions: Hematopoietic Cell Transplantation
I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients
Recruiting
The goal of this project is to rapidly screen promising agents, in the setting of an adaptive platform trial, for treatment of critically ill COVID-19 patients. In this phase 2 platform design, agents will be identified with a signal suggesting a big impact on reducing mortality and the need for, as well as duration, of mechanical ventilation.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/12/2024
Locations: Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, North Carolina
Conditions: COVID-19